ICI-170809
Chemical compound
ICI-170809 is a chemical compound that acts as a selective 5-HT4 receptor agonist. It was developed for its potential therapeutic effects on cognitive disorders and gastrointestinal motility disorders.
Chemical Properties[edit | edit source]
ICI-170809 is a synthetic compound with a complex chemical structure. It is characterized by its ability to selectively bind to and activate the 5-HT4 receptor, a subtype of the serotonin receptor family. This receptor is primarily found in the central nervous system and the gastrointestinal tract.
Pharmacology[edit | edit source]
ICI-170809 functions as a potent agonist at the 5-HT4 receptor. Activation of this receptor is known to enhance the release of acetylcholine in the brain, which is associated with improved cognitive function. This makes ICI-170809 a compound of interest in the study of neurodegenerative diseases such as Alzheimer's disease.
In the gastrointestinal system, 5-HT4 receptor activation by ICI-170809 can lead to increased gastrointestinal motility, making it a potential treatment for conditions like irritable bowel syndrome and chronic constipation.
Research and Development[edit | edit source]
Research into ICI-170809 has primarily focused on its effects on cognitive enhancement and gastrointestinal motility. Preclinical studies have shown promising results in animal models, where the compound improved memory and learning capabilities. However, further research is needed to fully understand its efficacy and safety in humans.
Potential Therapeutic Uses[edit | edit source]
ICI-170809 has been investigated for several potential therapeutic applications:
- Cognitive Disorders: Due to its action on the 5-HT4 receptor, ICI-170809 may help in the treatment of cognitive impairments associated with neurodegenerative diseases.
- Gastrointestinal Disorders: Its ability to enhance gastrointestinal motility suggests potential use in treating conditions like irritable bowel syndrome and chronic constipation.
Safety and Side Effects[edit | edit source]
As with any pharmacological agent, the safety profile of ICI-170809 is a critical aspect of its development. While preclinical studies have not shown significant adverse effects, comprehensive clinical trials are necessary to establish its safety in humans.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
